Helius Medical Technologies, Inc. (HSDT)
NASDAQ: HSDT · Real-Time Price · USD
4.270
+0.070 (1.67%)
At close: May 13, 2025, 4:00 PM
4.350
+0.080 (1.87%)
Pre-market: May 14, 2025, 7:54 AM EDT
Company Description
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma.
The company’s product is Portable Neuromodulation Stimulator, a non- implantable medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise.
The company is headquartered in Newtown, Pennsylvania.
Helius Medical Technologies, Inc.
| Country | United States |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 21 |
| CEO | Dane Andreeff |
Contact Details
Address: 642 Newtown Yardley Road, Suite 100 Newtown, Pennsylvania 18940 United States | |
| Phone | 215 944 6100 |
| Website | heliusmedical.com |
Stock Details
| Ticker Symbol | HSDT |
| Exchange | NASDAQ |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001610853 |
| CUSIP Number | 42328V884 |
| ISIN Number | US42328V8845 |
| Employer ID | 36-4787690 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Dane Carl Andreeff | President, Chief Executive Officer and Director |
| Jeffrey S. Mathiesen CPA | Chief Financial Officer, Treasurer, Secretary and Director |
| Dr. Antonella Favit-Van Pelt M.D., Ph.D. | Chief Medical Officer |
| Lawrence Picciano | Senior Vice President of Engineering, Quality and Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 2, 2025 | DEF 14A | Other definitive proxy statements |
| May 1, 2025 | 10-Q | Quarterly Report |
| Apr 30, 2025 | 8-K | Current Report |
| Apr 25, 2025 | 8-K | Current Report |
| Apr 22, 2025 | PRE 14A | Other preliminary proxy statements |
| Apr 22, 2025 | 8-K | Current Report |
| Apr 4, 2025 | 8-K | Current Report |
| Apr 4, 2025 | ARS | Filing |
| Mar 27, 2025 | EFFECT | Notice of Effectiveness |
| Mar 26, 2025 | 424B5 | Filing |